Net Worth Advisory Group Buys Shares of 2,603 Cencora, Inc. (NYSE:COR)

Net Worth Advisory Group bought a new position in shares of Cencora, Inc. (NYSE:COR - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 2,603 shares of the company's stock, valued at approximately $586,000.

Other large investors also recently bought and sold shares of the company. Rise Advisors LLC purchased a new position in Cencora in the first quarter valued at $25,000. New Millennium Group LLC purchased a new stake in Cencora during the second quarter worth approximately $26,000. TCTC Holdings LLC acquired a new position in Cencora in the first quarter valued at approximately $29,000. TFO Wealth Partners LLC purchased a new position in Cencora in the first quarter valued at approximately $30,000. Finally, MFA Wealth Advisors LLC acquired a new stake in Cencora during the second quarter worth approximately $30,000. Hedge funds and other institutional investors own 97.52% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently commented on COR. Robert W. Baird dropped their target price on shares of Cencora from $287.00 to $283.00 and set an "outperform" rating on the stock in a research report on Friday, September 6th. Bank of America reissued a "neutral" rating and issued a $245.00 target price (down from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Evercore ISI cut their price target on Cencora from $270.00 to $250.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 8th. JPMorgan Chase & Co. increased their price objective on Cencora from $280.00 to $287.00 and gave the company an "overweight" rating in a report on Wednesday, August 21st. Finally, Wells Fargo & Company lifted their target price on shares of Cencora from $236.00 to $249.00 and gave the company an "equal weight" rating in a report on Thursday, August 1st. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, Cencora currently has an average rating of "Moderate Buy" and a consensus target price of $259.44.

Cencora Stock Performance

NYSE COR traded up $1.79 during trading hours on Friday, hitting $237.43. 1,210,073 shares of the stock were exchanged, compared to its average volume of 1,423,747. The company has a quick ratio of 0.55, a current ratio of 0.89 and a debt-to-equity ratio of 3.93. The company has a market cap of $47.36 billion, a price-to-earnings ratio of 25.98, a price-to-earnings-growth ratio of 1.40 and a beta of 0.44. Cencora, Inc. has a 12-month low of $182.75 and a 12-month high of $247.66. The stock has a 50-day moving average of $232.38 and a 200 day moving average of $230.95.

Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.18 by $0.16. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The business had revenue of $74.20 billion during the quarter, compared to the consensus estimate of $73.32 billion. During the same period in the prior year, the business posted $2.92 EPS. The company's revenue for the quarter was up 10.8% on a year-over-year basis. As a group, equities research analysts forecast that Cencora, Inc. will post 13.63 earnings per share for the current year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 9th were paid a $0.51 dividend. This represents a $2.04 annualized dividend and a dividend yield of 0.86%. The ex-dividend date was Friday, August 9th. Cencora's dividend payout ratio (DPR) is 22.32%.

Insider Buying and Selling

In other news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of Cencora stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the completion of the sale, the insider now directly owns 19,980,000 shares in the company, valued at approximately $4,806,388,800. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Cencora news, EVP Silvana Battaglia sold 1,473 shares of Cencora stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total transaction of $357,482.37. Following the completion of the transaction, the executive vice president now owns 10,948 shares in the company, valued at approximately $2,656,970.12. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the completion of the sale, the insider now owns 19,980,000 shares in the company, valued at $4,806,388,800. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 15.80% of the stock is owned by insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.